Pharmala Biotech completes shipment to Johns Hopkins

Executive Summary

• Pharmala Biotech completed shipment of its LaNeo MDMA product to Johns Hopkins University, enabling U.S. investigator‑sponsored clinical trials.
• The company announced settlement of a $150,000 creditor debt by issuing 1,666,667 common shares at $0.09 per share.

Key Details

• Shipment of LaNeo MDMA from Pharmala’s newly onboarded U.S. distribution site to Johns Hopkins University was completed.
• Delivery is intended to support ongoing and future MDMA clinical trials in the United States, addressing prior sourcing challenges.
• CEO Nick Kadysh highlighted that the supply will accelerate data generation on MDMA efficacy for PTSD and other disorders.
• LaNeo MDMA is already used in global clinical trials and commercial medical applications in several countries; it is now imported, released, and ready for U.S. use under state and federal regulatory approval.
• Debt Settlement: $150,000 owed to an arm’s‑length creditor was settled by issuing 1,666,667 common shares at a deemed price of $0.09 per share.

Notable Quotes

“Our delivery to Johns Hopkins represents a new day for MDMA research in the United States… we believe that ensuring a supply for Pharmala's large and growing pool of clinical trial customers will ensure that data on MDMA's efficacy … becomes widely available.” – Nick Kadysh, CEO, Pharmala Biotech Holdings Inc.